S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
["Live Demo"] How to trade options in 30 seconds...  (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
Stop Day Trading - More Here (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
["Live Demo"] How to trade options in 30 seconds...  (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
Stop Day Trading - More Here (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
["Live Demo"] How to trade options in 30 seconds...  (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
Stop Day Trading - More Here (Ad)pixel
S&P 500   4,207.27
DOW   33,336.67
QQQ   324.08
Find and Profitably Trade Stocks at 52-Week Lows
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Why Invest in High-Yield Dividend Stocks?
3 Stable Growth Stocks for Bumpy Times
Disney (NYSE: DIS) Shares Just Gave Investors A Massive Signal
["Live Demo"] How to trade options in 30 seconds...  (Ad)pixel
Solar Stocks Shine Brightly After Passage Of Clean Energy Bill
Closing prices for crude oil, gold and other commodities
Big climate bill; Spending green bucks to boost green energy
Stop Day Trading - More Here (Ad)pixel
OTCMKTS:HCYTD

H-CYTE - HCYTD Stock Forecast, Price & News

$2.02
-1.98 (-49.50%)
(As of 07/11/2022)
Add
Compare
Today's Range
$2.02
▼
$2.77
50-Day Range
$0.02
▼
$4.00
52-Week Range
$2.02
▼
$77.00
Volume
400 shs
Average Volume
103 shs
Market Capitalization
$521,160.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
HCYTD stock logo

About H-CYTE (OTCMKTS:HCYTD) Stock

H-CYTE, Inc., a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease. The company is headquartered in Tampa, Florida.

Receive HCYTD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for H-CYTE and its competitors with MarketBeat's FREE daily newsletter.

HCYTD Stock News Headlines

August 7, 2022 | americanbankingnews.com
Head-To-Head Comparison: H-CYTE (OTCMKTS:HCYTD) versus NuVasive (NASDAQ:NUVA)
July 23, 2022 | apnews.com
H-CYTE to Expect the Completed Acquisition of Jantibody Within 30 Days
June 13, 2022 | finance.yahoo.com
H-CYTE Announces 1-for-1,000 Reverse Stock Split
March 4, 2022 | finance.yahoo.com
H-CYTE Announces Proceeds of $1.05 Million from Warrant Exercise
February 7, 2022 | nasdaq.com
H-CYTE Inc (HCYT)
January 11, 2022 | seekingalpha.com
H-CYTE signs letter of intent to acquire Catheter Precision
January 11, 2022 | finance.yahoo.com
H-CYTE Enters Into Letter of Intent for Acquisition of Catheter Precision, Inc.
December 6, 2021 | finance.yahoo.com
H-CYTE Names Michael Yurkowsky Chief Executive Officer
September 9, 2021 | au.finance.yahoo.com
Italian court seeks opinion on Berlusconi's health due to trial delays
September 8, 2021 | finance.yahoo.com
H-CYTE Combines Clinical Outcomes and Scientific Development to Launch New Centers for Respiratory Health
July 7, 2021 | ca.finance.yahoo.com
Jefferson Lines takes proactive steps toward crisis management with TSA I-STEP training
July 7, 2021 | in.finance.yahoo.com
Scanfil plc: Managers' transactions – Jokitalo
July 6, 2021 | finance.yahoo.com
H-CYTE Announces Publication of Additional Data that Further Supports Efficacy of Innovative PRP-PBMC Treatment Aimed at Helping to Improve Overall Lung Health
July 1, 2021 | in.finance.yahoo.com
Constellium supplies advanced aluminium solutions for the electric Audi e-tron GT
July 1, 2021 | au.finance.yahoo.com
NetNumber Named as One of the “10 Most Disruptive Companies of 2021” by Exceleon Magazine
June 29, 2021 | finance.yahoo.com
H-CYTE Announces Publication of Positive Real-World Data Relating to the Use of Innovative Treatment (PRP-PBMC) Aimed at Helping Improve Overall Lung Health
October 4, 2020 | msn.com
New Providence CEO: 'We have a responsibility and accountability to the community'
September 29, 2020 | feeds.benzinga.com
Robert Greif named Chief Executive Officer of H-CYTE
September 27, 2020 | marketwatch.com
Three Canada Stocks who's Volume Surged on Bullish Signals: $VS $PPR $QRO
September 2, 2020 | finance.yahoo.com
H-CYTE Extends Rights Offering to 5:00 PM Eastern Time on Friday, September 11, 2020
July 6, 2020 | www.nasdaq.com
TSX rises on energy gains, U.S. services sector rebound
July 6, 2020 | www.reuters.com
CANADA STOCKS-TSX rises on energy gains, U.S. services sector rebound
April 21, 2020 | finance.yahoo.com
Prairie Provident Provides an Update on Lending Facility
March 26, 2020 | www.globenewswire.com
Prairie Provident Resources Announces Fourth Quarter and Year-End 2019 Financial and Operating Results
February 18, 2020 | www.globenewswire.com
Prairie Provident Resources Announces Updated Corporate Presentation
See More Headlines
Receive HCYTD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for H-CYTE and its competitors with MarketBeat's FREE daily newsletter.

HCYTD Company Calendar

Today
8/11/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:HCYTD
CUSIP
N/A
CIK
1591165
Web
www.hcyte.com
Phone
(844) 633-6839
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-4,800,000.00
Net Margins
-450.40%
Pretax Margin
-450.40%
Return on Equity
N/A
Return on Assets
-777.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.12
Quick Ratio
0.12

Sales & Book Value

Annual Sales
$1.61 million
Price / Sales
0.32
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($31.45) per share
Price / Book
-0.06

Miscellaneous

Outstanding Shares
258,000
Free Float
244,000
Market Cap
$521,160.00
Optionable
Not Optionable
Beta
1.12

Key Executives

  • Mr. Michael W. Yurkowsky (Age 50)
    CEO & Director
    Comp: $180k
  • Mr. Jeremy Daniel (Age 46)
    Chief Financial Officer
    Comp: $200k
  • Dr. Tanya Rhodes Ph.D. (Age 61)
    Chief Scientific Officer
    Comp: $252k
  • Mr. Jeffery Wright CPA (Age 39)
    CPA, Controller & Principal Accounting Officer

Key Competitors

View All Competitors













HCYTD Stock - Frequently Asked Questions

How have HCYTD shares performed in 2022?

H-CYTE's stock was trading at $0.0569 at the start of the year. Since then, HCYTD shares have increased by 3,450.1% and is now trading at $2.02.
View the best growth stocks for 2022 here.

What is H-CYTE's stock symbol?

H-CYTE trades on the OTCMKTS under the ticker symbol "HCYTD."

How do I buy shares of H-CYTE?

Shares of HCYTD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is H-CYTE's stock price today?

One share of HCYTD stock can currently be purchased for approximately $2.02.

How much money does H-CYTE make?

H-CYTE (OTCMKTS:HCYTD) has a market capitalization of $521,160.00 and generates $1.61 million in revenue each year.

How can I contact H-CYTE?

H-CYTE's mailing address is 201 E Kennedy Blvd Suite 700, Tampa FL, 33602. The official website for the company is www.hcyte.com. The company can be reached via phone at (844) 633-6839 or via email at jassad@hcyte.com.

This page (OTCMKTS:HCYTD) was last updated on 8/12/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.